semaglutide diabetes trial Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 at high cardiovascular risk treated with experience more stable kidney function compared with placebo Semaglutide in patients with overweight

Peptides, Compounding Pharmacies, and the FDA: What Patients Actually Need to Know in 2026 There is a tremendous amount of confusion right now around peptides like BPC-157, TB-500, and GHK-Cu

This dual action of supporting inflammation regulation and potentially alleviating pain highlights its potential as a versatile therapeutic agent

In 2025, the global bone cement market was valued at Autologous Cell Therapy Market Outlook USD 9.31B-USD 54.83B How Is the Autologous Cell Therapy Market Redefining the Future of Precision Medicine

Two days later, Hims & Hers revealed it also bought a U.S.-based peptide facility based in California to expand its domestic supply chain